<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>New clinical, laboratory and experimental insights, since the 1999 publication of the Sapporo preliminary classification criteria for <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS), had been addressed at a workshop in Sydney, Australia, before the Eleventh International Congress on <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In this document, we appraise the existing evidence on clinical and laboratory features of APS addressed during the forum </plain></SENT>
<SENT sid="2" pm="."><plain>Based on this, we propose amendments to the Sapporo criteria </plain></SENT>
<SENT sid="3" pm="."><plain>We also provide definitions on features of APS that were not included in the updated criteria </plain></SENT>
</text></document>